[go: up one dir, main page]

MX2021003164A - Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas. - Google Patents

Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.

Info

Publication number
MX2021003164A
MX2021003164A MX2021003164A MX2021003164A MX2021003164A MX 2021003164 A MX2021003164 A MX 2021003164A MX 2021003164 A MX2021003164 A MX 2021003164A MX 2021003164 A MX2021003164 A MX 2021003164A MX 2021003164 A MX2021003164 A MX 2021003164A
Authority
MX
Mexico
Prior art keywords
methods
pancreatic cancer
patient
evaluation
cell
Prior art date
Application number
MX2021003164A
Other languages
English (en)
Inventor
Francois Collin
Chin - Jen Ku
Patrick A Arensdorf
Samuel Levy
Original Assignee
Bluestar Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluestar Genomics Inc filed Critical Bluestar Genomics Inc
Publication of MX2021003164A publication Critical patent/MX2021003164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/164—Methylation detection other then bisulfite or methylation sensitive restriction endonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Optimization (AREA)
  • Computational Mathematics (AREA)
  • Databases & Information Systems (AREA)
  • Mathematical Physics (AREA)
  • Public Health (AREA)
  • Mathematical Analysis (AREA)
  • Pure & Applied Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Operations Research (AREA)
  • Probability & Statistics with Applications (AREA)
  • Primary Health Care (AREA)
  • Algebra (AREA)
  • Evolutionary Biology (AREA)

Abstract

En este documento se describen métodos para identificar pacientes con cáncer de páncreas y sujetos en riesgo de desarrollar cáncer de páncreas, métodos para monitorear a un paciente con una lesión pancreática identificada, métodos para evaluar la efectividad de un tratamiento usado para un paciente con cáncer de páncreas y métodos para seleccionar una terapia para tratar el cáncer de páncreas en un paciente en particular. La invención hace uso de biomarcadores de hidroximetilación, que en combinación con uno o más parámetros clínicos y opcionalmente uno o más tipos adicionales de biomarcadores y/o factores de riesgo específicos del paciente, exhiben un nivel de hidroximetilación que se correlaciona con el cáncer de páncreas. También se proporcionan kits y otros métodos de uso.
MX2021003164A 2018-09-19 2019-09-19 Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas. MX2021003164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862733566P 2018-09-19 2018-09-19
PCT/US2019/052026 WO2020061380A1 (en) 2018-09-19 2019-09-19 Cell-free dna hydroxymethylation profiles in the evaluation of pancreatic lesions

Publications (1)

Publication Number Publication Date
MX2021003164A true MX2021003164A (es) 2021-06-23

Family

ID=68343435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003164A MX2021003164A (es) 2018-09-19 2019-09-19 Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.

Country Status (9)

Country Link
US (2) US20200123616A1 (es)
EP (1) EP3853383A1 (es)
JP (2) JP2022501033A (es)
CN (1) CN113508181A (es)
AU (1) AU2019343931B2 (es)
CA (1) CA3112880A1 (es)
MX (1) MX2021003164A (es)
SG (1) SG11202102421PA (es)
WO (1) WO2020061380A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115851942A (zh) * 2020-12-22 2023-03-28 上海市第一人民医院 诊断标志物gata4在胰腺“炎癌转化”中的应用
WO2022271857A1 (en) * 2021-06-23 2022-12-29 Accuragen Holdings Limited Gene expression and cell-free dna methods and systems for disease detection
CA3249400A1 (en) * 2022-01-28 2023-08-03 Flagship Pioneering Innovations Vi, Llc COMPOSITIONS AND METHODS OF PRODUCTION AND USE OF AN IMMORTALIZED BANK
CN114807356B (zh) * 2022-05-19 2025-02-28 苏州大学 一种nppb基因dna羟甲基化标志物、引物及其应用
WO2024096538A1 (ko) * 2022-10-31 2024-05-10 주식회사 지씨지놈 간암 진단용 dna 메틸화 마커 및 이의 용도
CN118186057A (zh) * 2022-12-13 2024-06-14 深圳湾实验室 游离dna标志物的筛选方法、dna标志物及其应用
EP4684035A1 (en) * 2023-03-22 2026-01-28 ClearNote Health, Inc. Cell-free dna analysis in the detection and monitoring of pancreatic cancer using a combination of features
CN119577058A (zh) * 2024-11-19 2025-03-07 北京易聊科技有限公司 向量数据库复合检索方法
CN119570934A (zh) * 2024-12-05 2025-03-07 南京医科大学 一种乳腺恶性肿瘤和乳腺良性肿瘤鉴别诊断标志物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712126A (en) 1995-08-01 1998-01-27 Yale University Analysis of gene expression by display of 3-end restriction fragments of CDNA
US6287825B1 (en) 1998-09-18 2001-09-11 Molecular Staging Inc. Methods for reducing the complexity of DNA sequences
AU2004251890B2 (en) 2003-06-25 2010-09-23 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
US7537897B2 (en) 2006-01-23 2009-05-26 Population Genetics Technologies, Ltd. Molecular counting
CN101720359A (zh) 2007-06-01 2010-06-02 454生命科学公司 从多重混合物中识别个别样本的系统和方法
US20090093378A1 (en) 2007-08-29 2009-04-09 Helen Bignell Method for sequencing a polynucleotide template
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
US20100323348A1 (en) 2009-01-31 2010-12-23 The Regents Of The University Of Colorado, A Body Corporate Methods and Compositions for Using Error-Detecting and/or Error-Correcting Barcodes in Nucleic Acid Amplification Process
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
WO2011127136A1 (en) * 2010-04-06 2011-10-13 University Of Chicago Composition and methods related to modification of 5-hydroxymethylcytosine (5-hmc)
MX341517B (es) * 2010-08-13 2016-08-24 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
HUE068153T2 (hu) 2011-04-15 2024-12-28 Univ Johns Hopkins Biztonságos szekvenálási rendszer
WO2012178034A2 (en) * 2011-06-23 2012-12-27 The Johns Hopkins University Mutations in pancreatic neoplasms
SMT202100154T1 (it) 2012-02-17 2021-05-07 Hutchinson Fred Cancer Res Composizioni e metodi per identificare precisamente mutazioni
EP2828218B9 (en) 2012-03-20 2021-04-07 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
SG11201808775PA (en) 2016-04-07 2018-11-29 Univ Leland Stanford Junior Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna
US20170298422A1 (en) 2016-04-18 2017-10-19 The Board Of Trustees Of The Leland Stanford Junior University Simultaneous single-molecule epigenetic imaging of dna methylation and hydroxymethylation
CN107385050A (zh) * 2017-08-04 2017-11-24 上海易毕恩生物技术有限公司 用于检测胰腺癌的基因标志物、试剂盒及胰腺癌检测方法
CA3091335A1 (en) 2018-02-14 2019-08-22 Bluestar Genomics, Inc. Methods for the epigenetic analysis of dna, particularly cell-free dna

Also Published As

Publication number Publication date
JP2022501033A (ja) 2022-01-06
CA3112880A1 (en) 2020-03-26
US20200123616A1 (en) 2020-04-23
WO2020061380A1 (en) 2020-03-26
AU2019343931A1 (en) 2021-05-13
EP3853383A1 (en) 2021-07-28
SG11202102421PA (en) 2021-04-29
WO2020061380A9 (en) 2020-05-28
CN113508181A (zh) 2021-10-15
AU2019343931B2 (en) 2026-02-05
US20240026459A1 (en) 2024-01-25
JP2024149826A (ja) 2024-10-18

Similar Documents

Publication Publication Date Title
MX2021003164A (es) Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas.
PH12022550578A1 (en) Method for identifying responders to smarca2/4 degraders
Robison et al. Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone
ZA202000935B (en) Methods and materials for assessing and treating cancer
WO2007109571A3 (en) Methods of predicting and monitoring tyrosine kinase inhibitor therapy
HK1259386A1 (zh) 与白介素-33 (il-33)介导的疾病有关的生物标志物及其用途
WO2020154268A3 (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
TN2017000502A1 (en) Methods of diagnosing and treating cancer
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2005010486A3 (en) Biomarker panel for colorectal cancer
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
WO2004001072A3 (en) Method for diagnosis of colorectal tumors
WO2017070114A3 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
MX2022016061A (es) Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
Ahmed et al. Role of resection and adjuvant therapy in long-term disease outcomes for low-grade pediatric intramedullary spinal cord tumors
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
Moratin et al. The occurrence of cervical metastases in squamous cell carcinoma of the tongue: is there a rationale for bilateral neck dissection in early-stage tumors?
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
MY209272A (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
AR085837A1 (es) Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer
EA202090439A1 (ru) Способы и материалы для оценки и лечения рака
WO2015121737A3 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure